The Future Is Now: New Treatment Options for Tardive Dyskinesia in 2017

Activity Details
  • Credit Amounts:
  • Cost: Free
  • Release: Aug 11, 2017
  • Expires: Aug 11, 2018
  • Average User Rating:
    ( Ratings)

To complete activity click here

 

Faculty

 This activity has 4 faculty members associated with it.
Click Here to View All
Jason Caplan Jason Caplan, MD, FAPM, FAPA
Creighton University School of Medicine
St. Joseph’s Hospital and Medical Center
Phoenix, AZ

Barbara Jones Warren Barbara Jones Warren, PhD, RN, PMHCNS-BC, FNAP, FAAN
Professor of Clinical Nursing
The Ohio State University
College of Nursing
Director, Psychiatric Nursing Program
Columbus, OH

Steven Stoner Steven Stoner, PharmD, BCPP
Chair and Clinical Professor
University of Missouri Kansas City
School of Pharmacy
Division of Pharmacy Practice and Administration
Kansas City, MO

Dawn Vanderhoef Dawn Vanderhoef, PhD, DNP, PMHNP-BC, FAANP
Director, Psychiatric Mental Health Nurse Practitioner (Lifespan) Specialty
Assistant Professor & Academic Director PMHNP Program
Vanderbilt University School of Nursing
Nashville, TN

Target Audience

Psychiatric-mental health nurses who care for psychiatric patients at risk for tardive dyskinesia.

Objectives

Upon completion of this activity, participants should be better able to:

  • Explain risk factors for development of tardive dyskinesia in the psychiatric practice setting
  • Using video cases, evaluate for drug-induced abnormal movements in patients at risk for developing tardive dyskinesia
  • Explore novel treatment options for tardive dyskinesia, considering efficacy, safety, and practical issues for the advanced practice psychiatric nurse
  • Demonstrate best practices the advanced practice nurse may employ in the frontline assessment of tardive dyskinesia and implementation of treatment protocols to improve patient outcomes

Faculty Disclosure

In accordance with the Food and Drug Administration, the speakers have disclosed that there is the potential for discussions concerning off-label uses of a commercial product/device during this educational activity.

Any person who may contribute to the content of this continuing education activity must disclose relevant relationships (and any known relationships of their spouse/partner) with commercial interests whose products or services are discussed in educational presentations. A commercial interest is defined as an entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on patients. Relevant relationships include receiving from a commercial interest research grants, consultant fees, travel, other benefits, or having a self-managed equity interest in a company.

Disclosure of a relationship is not intended to suggest or condone any bias in any presentation but is made to provide participants with information that might be of potential importance to their evaluation of a presentation.

Planner:
  • Joan B. Fowler, PharmD, BCPP: has no relevant financial relationships to disclose in relation to the content of this activity
Author/Presenters:
  • Jason P. Caplan, MD, FAPM, FAPA: has disclosed that he is a consultant for Avanir and Otsuka and a member of the speakers’ bureaus for Acadia, Avanir, and Neurocrine Biosciences, Inc.
  • Steven C. Stoner, PharmD, BCPP: has no relevant financial relationships to disclose in relation to the content of this activity
  • Barbara Jones Warren, PhD, RN, PMHCNS-BC, FNAP, FAAN: has no relevant financial relationships to disclose in relation to the content of this activity
  • Dawn M. Vanderhoef, PhD, DNP, PMHNP-BC, FAANP: has disclosed that she is a member of the speakers’ bureau for Neurocrine Biosciences, Inc.

Peer Reviewer:

Laura Thiem, DNP, RN, FNP-BC, PMHCNS-BC, PMHNP-BC, CNE: has no relevant financial relationships to disclose in relation to the content of this activity